Summary of Product Characteristics, Infanrix(R)-IPV+Hib. https://www.medicines.org. uk/emc/medicine/28678. Accessed March 2015.European Medicines Agency. Summary of Product Characteris- tics, 2010. EMA web site. Available at: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_...
由欧洲药品管理局(EMA)发布的关于Revised guideline on the summary of product characteristics for antimicrobial products(抗菌药物产品特性总结修订指南),来源于药智数据政策法规数据库。
PIL (product information leaflet)SmPC (Summary of Product Characteristics)The European Medicines Agency (EMA) has led the deEuropean... European,Biopharmaceutical,Enterprises - 《Gabi Journal》 被引量: 0发表: 2014年 Finding out about veterinary medicines authorised in the UK Product labelling The pro...
Xeljanz (tofacitinib): sum- mary of product characteristics. 2022. https://www.ema. europa.eu/en/documents/product-information/xeljanz-epar- product-information_en.pdf Accessed June 2, 2022. 34. Charles-Schoeman C, Buch M, Dougados M, et al. Risk factors for...
1. Introduction to the problem of bone tissue engineering 2. Biointeractions between bone scaffolds and the cells 3. In vitro cellular models for biomaterial biocompatibility testing 4. Conclusion and final remarks ReferencesShow full outline Cited by (148) Figures (10) Show 4 more figuresMaterial...
1. The obvious regional characteristics restrict the external development. 2. The positioning of brand consumption is not very clear, resulting in the style of many products is not centralized. 3. Lack of brand power. 4. The cost of family management is high. ...
On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior system...
Source: European Patients Academy (EUPATI) (2015), Development of medicines.5 Permission granted to reprint. The roundtable started with discussing the EMA approval process, which has become more flexible in recent years in response to the growth of personalised medicine and immune-oncology. ...
how do you think of LNTH? Is this a kind of climax top? I don't view it that way. It seems to be holding in an uptrend not going parabolic at the moment. Doesn't have those other climax characteristics: huge move in a short per...
For more extensive recommendations, please refer to the individual summary of product characteristics. Table 3 Side effects of lipid-lowering agents Full size table Recommendation for when to stop lipid-lowering agents CVD is prevalent in older people; however, evidence for risk reduction by lipid ...